In situ expression of B7 and CD28 receptor families in human malignant melanoma: Relevance for T-cell-mediated anti-tumor immunity
✍ Scribed by Ralf W. Denfeld; Andrea Dietrich; Christiane Wuttig; Eszter Tanczos; Johannes M. Weiss; Wolfgang Vanscheidt; Erwin Schöpf; Jan C. Simon
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- French
- Weight
- 977 KB
- Volume
- 62
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Work in animal models has suggested that interactions of members of the 87 receptor family (e.g., 87-I, 87-2) on tumor cells with their ligands CD28 and CTLA-4 on cytotoxic T cells (CTL) are important for the induction of anti-tumor immunity against malignant melanoma (MM). To determine whether these molecules are of relevance for CTL responses against human MM, we studied the expression of 87-I, 87-2, CD28 and CTLA-4 in primary tumors of MM (PMM), MM metastases (MMM) and benign melanocytic nevi (BMN) by immunohistochemistry (IH) and by reverse transcription polymerase chain reaction (RT-PCR). By RT-PCR, 87-I and B7-2-specific mRNAs were detected in most PMM, MMM and BMN. These PCRsignals were derived from CD45+-infiltrating leukocytes and not from tumor cells since (I) MMM depleted of CD45+ cells contained no B7-I or B7-2 mRNA; and (2) by IH, 87-I and B7-2 were found on infiltrating dendritic cells, macrophages and a variable proportion of tumor-infiltrating lymphocytes (TIL) but not on melanoma cells or nevus cells. The important exceptions were 5/5 spontaneously regressing PMM, in which 87-1 and B7-2 were expressed by melanoma cells, that were surrounded by TIL expressing CD28 but not CTLA-4. We conclude that, in PMM, MMM and BMN, the majority of TIL are CD28+ and that 87-I and 87-2 are expressed by CD45+-infiltrating antigen-'To whom correspondence and reprint requests should be sent, at